NASDAQ:DXCM - Dexcom Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $103.52 +1.78 (+1.75 %) (As of 07/18/2018 04:00 PM ET)Previous Close$101.74Today's Range$101.13 - $103.7852-Week Range$42.62 - $105.46Volume772,202 shsAverage Volume1.14 million shsMarket Capitalization$8.76 billionP/E Ratio-178.60Dividend YieldN/ABeta0.01 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. Receive DXCM News and Ratings via Email Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:DXCM CUSIP25213110 Webwww.dexcom.com Phone858-200-0200 Debt Debt-to-Equity Ratio0.79 Current Ratio5.83 Quick Ratio5.42 Price-To-Earnings Trailing P/E Ratio-178.60 Forward P/E Ratio-199.08 P/E GrowthN/A Sales & Book Value Annual Sales$718.50 million Price / Sales12.69 Cash FlowN/A Price / CashN/A Book Value$4.83 per share Price / Book21.43 Profitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-50,200,000.00 Net Margins-4.30% Return on Equity-9.32% Return on Assets-4.28% Miscellaneous Employees2,990 Outstanding Shares88,080,000Market Cap$8,760.05 Dexcom (NASDAQ:DXCM) Frequently Asked Questions What is Dexcom's stock symbol? Dexcom trades on the NASDAQ under the ticker symbol "DXCM." How were Dexcom's earnings last quarter? Dexcom (NASDAQ:DXCM) issued its earnings results on Wednesday, May, 2nd. The medical device company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). The medical device company earned $184.40 million during the quarter, compared to the consensus estimate of $172.66 million. Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. Dexcom's quarterly revenue was up 29.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.49) EPS. View Dexcom's Earnings History. When is Dexcom's next earnings date? Dexcom is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Dexcom. What price target have analysts set for DXCM? 21 equities research analysts have issued 1-year price targets for Dexcom's stock. Their forecasts range from $40.00 to $116.00. On average, they anticipate Dexcom's stock price to reach $77.2059 in the next twelve months. This suggests that the stock has a possible downside of 25.5%. View Analyst Ratings for Dexcom. What is the consensus analysts' recommendation for Dexcom? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dexcom in the last year. There are currently 2 sell ratings, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Dexcom's key competitors? Some companies that are related to Dexcom include ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC) and Nevro (NVRO). Who are Dexcom's key executives? Dexcom's management team includes the folowing people: Mr. Kevin R. Sayer, Chief Exec. Officer, Pres and Director (Age 60)Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 46)Mr. Richard B. Doubleday, Chief Commercial Officer and Exec. VP (Age 55)Mr. Donald M. Abbey, Exec. VP of Quality & Regulatory Affairs (Age 51)Mr. Terrance H. Gregg, Exec. Chairman (Age 69) Has Dexcom been receiving favorable news coverage? News stories about DXCM stock have been trending somewhat negative on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dexcom earned a media sentiment score of -0.15 on Accern's scale. They also gave media headlines about the medical device company an impact score of 46.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are Dexcom's major shareholders? Dexcom's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (5.90%), Peregrine Capital Management LLC (0.33%), Bank of Montreal Can (0.04%), Patten & Patten Inc. TN (0.03%), Xact Kapitalforvaltning AB (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Dexcom stock include Andrew K Balo, Barbara Kahn, Eric Topol, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for Dexcom. Which institutional investors are selling Dexcom stock? DXCM stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co.. Company insiders that have sold Dexcom company stock in the last year include Andrew K Balo, Barbara Kahn, Eric Topol, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for Dexcom. Which institutional investors are buying Dexcom stock? DXCM stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Peregrine Capital Management LLC, State of Alaska Department of Revenue, Patten & Patten Inc. TN, Clinton Group Inc., Cerebellum GP LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Dexcom. How do I buy shares of Dexcom? Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dexcom's stock price today? One share of DXCM stock can currently be purchased for approximately $103.59. How big of a company is Dexcom? Dexcom has a market capitalization of $8.76 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Dexcom employs 2,990 workers across the globe. How can I contact Dexcom? Dexcom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected] MarketBeat Community Rating for Dexcom (NASDAQ DXCM)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 607 (Vote Outperform)Underperform Votes: 312 (Vote Underperform)Total Votes: 919MarketBeat's community ratings are surveys of what our community members think about Dexcom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?